Cor Vasa 2022, 64(Suppl. 4):18-30

The year in cardiovascular medicine 2021: dyslipidaemia

Lale Tokgozoglu1*, Carl Orringer2, Henry N. Ginsberg3, Alberico L. Catapano4
1 Department of Cardiology, Hacettepe University Faculty of Medicine, Sıhhiye, 06100 Ankara, Turkey
2 Department of Preventive Cardiovascular Medicine, Cardiovascular Division, University of Miami Miller School of Medicine, Miami, FL, USA
3 Department of Medicine, Vagelos College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA
4 Department of Pharmacological and Biomolecular Sciences, University of Milan and IRCCS Multimedica, Milano, Italy

Received Date: 02 October 2021; Accepted Date: 16 November 2021
Reproduced from: Tokgozoglu L, Orringer C, Ginsberg HN, Catapano AL. The year in cardiovascular medicine 2021: dyslipidaemia. Eur Heart J 2022;43:807–817. https://doi.org/10.1093/eurheartj/ehab875, by permission of Oxford University Press on behalf of the European Society of Cardiology

The past year was an exciting time for clinical lipidology when we learnt more about existing therapies as well as therapies targeting novel pathways discovered through genetic studies. LDL cholesterol remained the main target and a variety of drugs to lower LDL cholesterol through different mechanisms were explored. Emerging evidence on the atherogenity of triglyceride-rich lipoproteins led to renewed interest in lowering them with new treatments. Lp(a) was back in focus with evidence on causality and new targeted therapeutics which dramatically lower Lp(a) levels. We will be able to personalise lipid lowering therapy further with this enriched armamentarium once we have the results of the cardiovascular outcome studies with some of these new agents.

Keywords: Cardiovascular diseases; Lipids; Nucleic acid therapeutics; RNA interference; Antisense; CRISPR; LDL-C. Triglycerides;Lp(a); Statins; PCSK9 inhibitors

Received: December 21, 2022; Accepted: December 21, 2022; Published: December 30, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tokgozoglu L, Orringer C, Ginsberg HN, Catapano AL. The year in cardiovascular medicine 2021: dyslipidaemia. Cor Vasa. 2022;64(Suppl. 4):18-30.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021;42:3227-3337. Go to original source... Go to PubMed...
    2. ach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-188. Go to original source... Go to PubMed...
    3. Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, et al Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J 2021;42:243-252. Go to original source... Go to PubMed...
    4. Vallejo-Vaz AJ, Stevens CAT, Lyons ARM, Dharmayat KI, Freiberger T, Hovingh GK, et al Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet 2021;398:1713-1725. Go to original source... Go to PubMed...
    5. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2021-2031. Go to original source... Go to PubMed...
    6. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, et al Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J 2018;39:2526-2539. Go to original source... Go to PubMed...
    7. Herrett E, Williamson E, Brack K, Beaumont D, Perkins A, Thayne A, et al Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ 2021;372:n135. Go to original source... Go to PubMed...
    8. Wood FA, Howard JP, Finegold JA, Nowbar AN, Thompson DM, Thompson DM, et al N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med 2020;383:2182-2184. Go to original source... Go to PubMed...
    9. Cai T, Abel L, Langford O, Monaghan G, Aronson JK, Stevens RJ, et al Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ 2021;374:n1537. Go to original source... Go to PubMed...
    10. Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8:e011662. Go to original source... Go to PubMed...
    11. Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol 2020;27:593-603. Go to original source... Go to PubMed...
    12. Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial. Atherosclerosis 2021;320:122-128. Go to original source... Go to PubMed...
    13. Guedeney P, Giustino G, Sorrentino S, Claessen BE, Camaj A, Kalkman DN, et al Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J 2019;ehz430. doi:10.1093/eurheartj/ehz430. Published online ahead of print. Go to original source... Go to PubMed...
    14. Sabatine MS. PCSK9 inhibitors: what we know, what we should have understood, and what is to come. Eur Heart J 2019;ehz514. doi:10.1093/eurheartj/ehz514 Go to original source... Go to PubMed...
    15. Murphy SA, Pedersen TR, Gaciong ZA, Ceska R, Ezhov MV, Connolly DL, et al Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial. JAMA Cardiol 2019;4:613-619. Go to original source... Go to PubMed...
    16. Oyama K, Giugliano RP, Tang M, Bonaca MP, Saver JL, Murphy SA, et al Effect of evolocumab on acute arterial events across all vascular territories: results from the FOURIER trial. Eur Heart J 2021;ehab604. doi:10.1093/eurheartj/ehab604. Go to original source... Go to PubMed...
    17. Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, et al Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol. J Am Coll Cardiol 2021;78:421-433. Go to original source... Go to PubMed...
    18. Schwartz GG, Gabriel Steg P, Bhatt DL, Bittner VA, Diaz R, Goodman SG, et al Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol: a propensity score-matched analysis of the ODYSSEY OUTCOMES trial. Circulation 2021;143:1109-1122. Go to original source... Go to PubMed...
    19. Qi Z, Hu L, Zhang J, Yang W, Liu X, Jia D, et al PCSK9 (proprotein convertase subtilisin/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36. Circulation 2021;143(1):45-61. Go to original source... Go to PubMed...
    20. Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, et al The effect of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition on the risk of venous thromboembolism. Circulation 2020;141:1600-1607. Go to original source... Go to PubMed...
    21. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al Cognitive function in a randomized trial of evolocumab. N Engl J Med 2017;377:633-643. Go to original source... Go to PubMed...
    22. Gencer B, Mach F, Guo J, Im K, Ruzza A, Wang H, et al Cognition after lowering LDL-cholesterol with evolocumab. J Am Coll Cardiol 2020;75:2283-2293. Go to original source... Go to PubMed...
    23. Janik MJ, Urbach DV, van Nieuwenhuizen E, Zhao J, Yellin O, Baccara-Dinet MT, et al Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: a prospective, randomized, placebo-controlled study. Atherosclerosis 2021;331:20-27. Go to original source... Go to PubMed...
    24. Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J 2021;42:4791-4806. Go to original source... Go to PubMed...
    25. Quispe R, Martin SS, Michos ED, Lamba I, Blumenthal RS, Saeed A, et al Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. Eur Heart J 2021;42:4324-4332. Go to original source... Go to PubMed...
    26. Borén J, Packard CJ. Keeping remnants in perspective. Eur Heart J 2021;42:4333-4335. Go to original source... Go to PubMed...
    27. Raposeiras-Roubin S, Rosselló X, Oliva B, Fernández-Friera L, Mendiguren JM, Andrés V, et al Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol 2021;77:3031-3041. Go to original source... Go to PubMed...
    28. Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med 2019;381:531-542. Go to original source... Go to PubMed...
    29. Ahmad Z, Banerjee P, Hamon S, Chan KC, Bouzelmat A, Sasiela WJ, et al Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation 2019;140:470-486. Go to original source... Go to PubMed...
    30. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11-22. Go to original source... Go to PubMed...
    31. Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Brinton EA, et al Reduction in revascularization with icosapent ethyl. Circulation 2021;143:33-44. Go to original source... Go to PubMed...
    32. Lakshmanan S, Shekar C, Kinninger A, Golub I, Hamal S, Birudaraju D, et al Effect of icosapent ethyl on percent atheroma volume in patients with elevated triglycerides on statin therapy - insights from the evaporate trial. J Am Coll Cardiol 2021;77(18, Supplement 1):1279. Go to original source...
    33. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA 2020;324:2268-2280. Go to original source... Go to PubMed...
    34. Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, et al Effects of n-3 fatty acid supplements in elderly patients after myocardial infarction. Circulation 2021;143:528-539. Go to original source... Go to PubMed...
    35. Pirillo A, Catapano AL. Omega-3 for cardiovascular diseases: where do we stand after REDUCE-IT and STRENGTH? Circulation 2021;144:183-185. Go to original source... Go to PubMed...
    36. Doi T, Langsted A, Nordestgaard BG. A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs. Eur Heart J 2021;42:4777-4780. Go to original source... Go to PubMed...
    37. FDA (Food and Drug Administration). Endocrinologic and metabolic drugs advisory committee briefing document. 2019.
    38. Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arterioscler Thromb Vasc Biol 2020;40:1135-1147. Go to original source... Go to PubMed...
    39. Jacobs ML, Faizi HA, Peruzzi JA, Vlahovska PM, Kamat NP. EPA and DHA differentially modulate membrane elasticity in the presence of cholesterol. Biophys J 2021;120:2317-2329. Go to original source... Go to PubMed...
    40. So J, Wu D, Lichtenstein AH, Tai AK, Matthan NR, Maddipati KR, et al EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: a randomized, double-blind, crossover study. Atherosclerosis 2021;316:90-98. Go to original source... Go to PubMed...
    41. Bittner DO, Goeller M, Dey D, Zopf Y, Achenbach S, Marwan M, et al High levels of eicosapentaenoic acid are associated with lower pericoronary adipose tissue attenuation as measured by coronary CTA. Atherosclerosis 2021;316:73-78. Go to original source... Go to PubMed...
    42. Berg K. A new serum type system in man-the LP system. Acta Pathol Microbiol Scand 1963;59:369-382. Go to original source... Go to PubMed...
    43. Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, et al Lp(a) (lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank. Arterioscler Thromb Vasc Biol. 2021;41:465-474. Go to original source... Go to PubMed...
    44. Satterfield BA, Dikilitas O, Safarova MS, Clarke SL, Tcheandjieu C, Zhu X, et al Associations of genetically predicted Lp(a) (lipoprotein [a]) levels with cardiovascular traits in individuals of European and African Ancestry. Circ Genom Precis Med 2021;14:e003354. Go to original source... Go to PubMed...
    45. Langsted A, Nordestgaard BG, Kamstrup PR. Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study. Eur Heart J 2021;42:1147-1156. Go to original source... Go to PubMed...
    46. Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, et al Relation of lipoprotein(a) levels to incident type 2 diabetes and modification by alirocumab treatment. Diabetes Care 2021;44:1219-1227. Go to original source... Go to PubMed...
    47. Schachtl-Riess JF, Kheirkhah A, Grüneis R, Di Maio S, Schoenherr S, Streiter G, et al Frequent LPA KIV-2 variants lower lipoprotein(a) concentrations and protect against coronary artery disease. J Am Coll Cardiol 2021;78:437-449. Go to original source... Go to PubMed...
    48. Mukamel RE, Handsaker RE, Sherman MA, Barton AR, Zheng Y, McCarroll SA, et al Protein-coding repeat polymorphisms strongly shape diverse human phenotypes. bioRxiv 2021. doi:10.1101/2021.01.19.427332. Go to original source... Go to PubMed...
    49. Willeit P, Yeang C, Moriarty PM, Tschiderer L, Varvel SA, McConnell JP, et al Low-density lipoprotein cholesterolcorrected for lipoprotein(a) cholesterol, risk thresholds, and cardiovascular events. J Am Heart Assoc. 2020;9:e016318. Go to original source... Go to PubMed...
    50. Yeang C, Witztum JL, Tsimikas S. Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. J Lipid Res 2021;62:100053. Go to original source... Go to PubMed...
    51. Miksenas H, Januzzi JL Jr, Natarajan P. Lipoprotein(a) and cardiovascular diseases. JAMA 2021;326:352-353. Go to original source... Go to PubMed...
    52. Ray KK, Wright RS, Kallend D, Koenig W, Koenig W, Raal FJ, et al Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med 2020;382:1507-1519. Go to original source... Go to PubMed...
    53. Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med 2020;382:1520-1530. Go to original source... Go to PubMed...
    54. Khan SA, Naz A, Qamar Masood M, Shah R. Meta-analysis of inclisiran for the treatment of hypercholesterolemia. Am J Cardiol 2020;134:69-73. Go to original source... Go to PubMed...
    55. Wright RS, Ray KK, Raal FJ, Kallend DG, Jaros M, Jaros M, et al Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol 2021;77:1182-1193. Go to original source... Go to PubMed...
    56. Hovingh GK, Lepor NE, Kallend D, Stoekenbroek RM, Wijngaard PLJ, Raal FJ, et al Inclisiran durably lowers low-density lipoprotein cholesterol and proprotein convertase subtilisin/kexin type 9 expression in homozygous familial hypercholesterolemia: the ORION-2 pilot study. Circulation 2020;141:1829-1831. Go to original source... Go to PubMed...
    57. A study of inclisiran in participants with homozygous familial hypercholesterolemia (HoFH) (ORION-5). https://www.clinicaltrials.gov/ct2/show/NCT03851705 (27 September 2021, date last accessed).
    58. A randomized trial assessing the effects of inclisiran on clinical outcomes among people with cardiovascular disease (ORION-4). https://clinicaltrials.gov/ct2/show/NCT03705234 (27 September 2021, date last accessed).
    59. Landmesser U, Haghikia A, Leiter LA, Wright RS, Kallend D, Wijngaard P, et al Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovas Res 2021;117: 284-291. Go to original source... Go to PubMed...
    60. Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Kingsbury J, et al Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J 2020;41:3936-3945. Go to original source... Go to PubMed...
    61. Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 2020;382:244-255. Go to original source... Go to PubMed...
    62. Olpasiran trials of cardiovascular events and lipoproteiN(a) reduction - DOSE finding study. https://clinicaltrials.gov/ct2/show/NCT04270760 (27 September 2021, date last accessed).
    63. Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Hovingh GK, Hovingh GK, et al Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med 2020;383:711-720. Go to original source... Go to PubMed...
    64. Reeskamp LF, Millar JS, Wu L, Jansen H, van Harskamp D, Schierbeek H, et al ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia-brief report. Arterioscler Thromb Vasc Biol 2021;41:1753-1759. Go to original source... Go to PubMed...
    65. Reeskamp LF, Nurmohamed NS, Bom MJ, Planken RN, Driessen RS, Driessen RS, et al Marked plaque regression in homozygous familial hypercholesterolemia. Atherosclerosis 2021;327:13-17. Go to original source... Go to PubMed...
    66. Rosenson RS, Burgess LJ, Ebenbichler CF, Baum SJ, Stroes ESG, Ali S, et al Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med 2020;383:2307-2319. Go to original source... Go to PubMed...
    67. Ahmad Z, Pordy R, Rader DJ, Gaudet D, Gaudet D, Gonzaga-Jauregui C, et al Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia. J Am Coll Cardiol 2021;78:193-195. Go to original source... Go to PubMed...
    68. Brousseau ME, Clairmont KB, Spraggon G, Flyer AN, Golosov AA, Grosche P, et al Identification of a PCSK9-LDLR disruptor peptide with in vivo function. Cell Chem Biol 2021. doi:10.1016/j.chembiol.2021.08.012. Published online ahead of print 20 September 2021. Go to original source... Go to PubMed...
    69. Zeitlinger M, Bauer M, Reindl-Schwaighofer R, Stoekenbroek RM, Lambert G, Berger-Sieczkowski E, et al A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. Eur J Clin Pharmacol 2021;77:1473-1484. Go to original source... Go to PubMed...
    70. Rothgangl T, Dennis MK, Lin PJC, Oka R, Witzigmann D, Villiger L, et al In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat Biotechnol 2021;39:949-957. Go to original source... Go to PubMed...
    71. Musunuru K, Chadwick AC, Mizoguchi T, Garcia SP, DeNizio JE, Reiss CW, et al In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 2021;593:429-434. Go to original source... Go to PubMed...
    72. Wang L, Breton C, Warzecha CC, Bell P, Yan H, He Z, et al Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9. Mol Ther 2021;29:2019-2029. Go to original source... Go to PubMed...
    73. Shyamala N, Gundapaneni KK, Galimudi RK, Tupurani MA, Padala C, Puranam K, et al PCSK9 genetic (rs11591147) and epigenetic (DNA methylation) modifications associated with PCSK9 expression and serum proteins in CAD patients. J Gene Med 2021;23:e3346. Go to original source... Go to PubMed...
    74. Liu X, Bao X, Hu M, Chang H, Jiao M, Cheng J, et al Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature 2020;588:693-698. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes